Bulk Pharmaceutical API Sources for doxazosin mesylate

Bulk Pharmaceutical API Sources for doxazosin mesylate

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		D9815_SIGMA
Molport		MolPort-003-983-427
Hangzhou APIChem Technology		AC-6848
Amadis Chemical		A839262
TCI (Tokyo Chemical Industry)		D4126

Doxazosin Mesylate Bulk API Sourcing Analysis

Last updated: February 19, 2026

Market Overview of Doxazosin Mesylate Bulk API

Doxazosin mesylate is an alpha-1 adrenergic blocker used to treat hypertension and benign prostatic hyperplasia (BPH). The global market for doxazosin mesylate API is characterized by established generic competition and a stable demand driven by the prevalence of its target conditions. Key sourcing considerations include regulatory compliance, cost-effectiveness, supply chain reliability, and quality control. Major manufacturing hubs are concentrated in India and China, with a growing presence of specialized API producers in other regions.

Key Doxazosin Mesylate API Manufacturers and Suppliers

Several companies supply bulk doxazosin mesylate API. These suppliers are assessed based on their Good Manufacturing Practice (GMP) certifications, regulatory filings (e.g., Drug Master Files - DMFs), production capacity, and pricing.

• Divi's Laboratories: A leading Indian API manufacturer with a strong global presence. Divi's is known for its large-scale production capabilities and robust quality systems. They hold numerous DMFs with regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Laurus Labs: Another prominent Indian API producer specializing in generic APIs. Laurus Labs has a diverse portfolio and significant manufacturing capacity, with facilities compliant with international regulatory standards.
• Granules India Ltd.: A vertically integrated pharmaceutical company that manufactures APIs and finished dosage forms. Granules India has a well-established regulatory track record and significant production volumes for various APIs, including doxazosin mesylate.
• Aarti Industries Ltd.: An Indian chemical manufacturing company with a substantial API division. Aarti Industries focuses on complex chemistries and has expanded its global reach in API supply.
• Zhejiang NHU Company Ltd.: A major Chinese pharmaceutical ingredient producer. NHU has a broad product range and invests heavily in R&D and quality compliance. Their facilities are designed to meet international GMP standards.

Regulatory Landscape for Doxazosin Mesylate API

The sourcing of doxazosin mesylate API is heavily influenced by stringent regulatory requirements. Compliance with GMP is non-negotiable. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Requires a U.S. DMF for API used in drugs marketed in the United States. Regular facility inspections are conducted to ensure ongoing compliance.
• European Medicines Agency (EMA): Requires a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) or an active substance master file (ASMF) for APIs used in the European Union.
• Other National Regulatory Authorities: Countries like Japan (PMDA), Canada (Health Canada), and Australia (TGA) have their own specific requirements for API registration and importation.

Manufacturers must provide detailed documentation regarding their manufacturing process, impurity profiles, stability data, and quality control procedures. Changes in manufacturing processes or facilities necessitate regulatory notification and potential re-validation.

Quality Control and Specification Standards

Ensuring the quality of bulk doxazosin mesylate API is paramount. Specifications typically include:

• Assay: The percentage of doxazosin mesylate present, usually not less than 98.0% and not more than 102.0% on the dried basis.
• Related Substances/Impurities: Strict limits are set for known and unknown impurities, as defined by pharmacopoeias (e.g., USP, EP) and ICH guidelines. Common impurities are often related to the synthesis pathway.
• Water Content: Typically determined by Karl Fischer titration, with specific limits (e.g., not more than 1.0%).
• Residue on Ignition (Sulfated Ash): Measures inorganic impurities, with a specified maximum percentage (e.g., not more than 0.1%).
• Heavy Metals: Limits for heavy metal contamination are enforced.
• Particle Size Distribution: Important for downstream processing and dissolution characteristics of the finished dosage form.
• Polymorphism: Doxazosin mesylate can exist in different polymorphic forms, which can affect solubility and bioavailability. Manufacturers must control and characterize the crystalline form.

Manufacturers must implement robust Quality Management Systems (QMS) that encompass raw material control, in-process testing, final product release testing, and stability studies.

Supply Chain Considerations for Doxazosin Mesylate API

Reliable supply chain management is critical for pharmaceutical manufacturing. For doxazosin mesylate, this involves:

• Supplier Qualification: A rigorous process for vetting potential API suppliers, including audits of their manufacturing facilities and quality systems.
• Lead Times: Understanding and managing lead times for API procurement, which can range from 8 to 24 weeks depending on the supplier and order volume.
• Inventory Management: Maintaining adequate inventory levels to buffer against supply disruptions without incurring excessive carrying costs.
• Geopolitical and Economic Factors: Awareness of potential disruptions stemming from trade disputes, natural disasters, or economic instability in key manufacturing regions.
• Logistics and Transportation: Ensuring secure and compliant transportation of API, maintaining temperature and handling requirements as needed.

Many drug manufacturers engage in dual or multi-sourcing strategies to mitigate risks associated with relying on a single supplier.

Cost Analysis and Pricing Trends

The pricing of bulk doxazosin mesylate API is influenced by raw material costs, manufacturing efficiency, scale of production, regulatory compliance costs, and market competition.

• Raw Material Costs: Fluctuations in the prices of key starting materials can impact API costs.
• Manufacturing Efficiency: Investment in process optimization and automation can lead to lower production costs.
• Scale of Production: Larger production volumes generally result in lower per-unit costs due to economies of scale.
• Regulatory Expenses: Costs associated with maintaining GMP compliance, filing DMFs, and undergoing audits are significant.
• Market Competition: The presence of multiple suppliers drives competitive pricing.

Current pricing for bulk doxazosin mesylate API can range from approximately $50 to $200 per kilogram, depending on the supplier, purity, volume purchased, and specific contractual terms. Long-term contracts often secure more favorable pricing.

Risk Assessment in Doxazosin Mesylate API Sourcing

Sourcing doxazosin mesylate API presents several risks:

• Quality Deviations: Batch failures due to out-of-specification results or contamination can halt production.
• Regulatory Non-Compliance: Failure to maintain GMP standards or pass regulatory inspections can lead to import alerts, product recalls, or manufacturing suspensions.
• Supply Chain Disruptions: Unforeseen events (e.g., plant shutdowns, transportation issues, geopolitical unrest) can interrupt the supply.
• Intellectual Property (IP) Issues: While doxazosin mesylate is off-patent, understanding the IP landscape related to novel manufacturing processes or polymorphs is crucial.
• Counterfeit Products: Risk of unknowingly sourcing counterfeit or substandard API, particularly from less reputable channels.

Mitigation strategies include robust supplier audits, stringent quality agreements, dual sourcing, and diligent regulatory intelligence monitoring.

Future Outlook for Doxazosin Mesylate API

The demand for doxazosin mesylate API is expected to remain stable, driven by the ongoing treatment needs for hypertension and BPH. The generic nature of the drug means that cost-efficiency and reliable supply will continue to be the primary competitive factors for API manufacturers.

Innovation in this segment is likely to focus on:

• Process Optimization: Developing more environmentally friendly and cost-effective synthesis routes.
• Impurity Profiling and Control: Enhanced analytical techniques for better identification and control of trace impurities.
• Supply Chain Transparency: Increased use of digital technologies to enhance visibility and traceability within the supply chain.

Established manufacturers with strong regulatory compliance and efficient production processes are best positioned to maintain market share. Emerging markets may present growth opportunities as healthcare access expands.

Key Takeaways

• Doxazosin mesylate API sourcing requires stringent adherence to global regulatory standards (FDA, EMA).
• Key suppliers are predominantly located in India and China, with Divi's Laboratories, Laurus Labs, Granules India, Aarti Industries, and Zhejiang NHU being prominent players.
• Quality control parameters are critical, including assay, impurity profiles, water content, and physical characteristics.
• Supply chain reliability is maintained through dual sourcing and robust supplier qualification.
• Pricing is competitive, generally ranging from $50-$200/kg, influenced by production scale and regulatory overhead.
• Risks include quality deviations, regulatory non-compliance, and supply chain disruptions.

Frequently Asked Questions

What are the primary regulatory requirements for sourcing doxazosin mesylate API?

Sourcing requires API to meet pharmacopoeial standards (e.g., USP, EP) and manufacturers must comply with GMP. Regulatory filings such as DMFs (U.S.) or CEPs/ASMFs (EU) are necessary for market approval of finished drug products.

Which countries are the dominant sources for bulk doxazosin mesylate API?

India and China are the primary manufacturing hubs for doxazosin mesylate API due to their established chemical and pharmaceutical industries and cost advantages.

What quality control tests are most critical for doxazosin mesylate API?

Critical tests include assay, related substances (impurities), water content, residue on ignition, and heavy metals. Particle size distribution and polymorphic form are also important for formulation.

How can supply chain risks be mitigated when sourcing doxazosin mesylate API?

Mitigation strategies include qualifying multiple suppliers, conducting thorough supplier audits, establishing clear quality agreements, and maintaining appropriate inventory levels to buffer against disruptions.

What is the typical lead time for procuring bulk doxazosin mesylate API?

Lead times can vary but generally range from 8 to 24 weeks, depending on the supplier's production schedule, order volume, and existing commitments.

What are the main factors influencing the price of doxazosin mesylate API?

Pricing is driven by raw material costs, manufacturing efficiency, scale of production, regulatory compliance expenses, and overall market competition among suppliers.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - Specific URL would be needed here if referencing a specific document] [2] European Medicines Agency. (n.d.). Active Substances. Retrieved from [EMA Website - Specific URL would be needed here if referencing a specific document] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website - Specific URL would be needed here if referencing a specific document] [4] United States Pharmacopeia. (n.d.). USP Monographs. Retrieved from [USP Website - Specific URL would be needed here if referencing a specific document] [5] European Pharmacopoeia. (n.d.). Ph. Eur. Monograph. Retrieved from [EDQM Website - Specific URL would be needed here if referencing a specific document]